StroMel not checked

Akan Biosciences, LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Osteo Arthritis Knee
Main trialPhase 1/2
“The aim of this trial is to evaluate the safety and tolerability of autologous StroMel™ for the treatment of moderate to severe OA of the knee joint.”In the company’s words, NCT04750252 on ClinicalTrials.gov

Other drugs for Osteo Arthritis Knee

All 48 drugs for Osteo Arthritis Knee

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 31 Aug 2027 Safety and Tolerability of StroMel™ in Subjects with Moderate to Severe Osteoarthritis of the Knee Joint
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow StroMel

Following is part of Solo: you see every change to StroMel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in